PCSS Half & Half Buprenorphine Training

Half & Half Buprenorphine Training

Buprenorphine for the Treatment of
Opioid Use Disorder

Audience

OB/GYNs
Pediatricians
Primary care providers
Certified nurse midwives
Advanced practice nurses
Physician assistants

Training Overview

The PCSS Half-and-Half Buprenorphine Training course provides an overview of the FDA-approved medication buprenorphine prescribed for the treatment of opioid use disorder (OUD). The course trainer will conduct an overview of prevention, identification, and treatment of substance use disorders emphasizing OUD.

The 8-hour buprenorphine training is offered in a ‘half and half’ format: 4 hours of in-person training followed by 4 hours of online training through PCSS. Upon completion of the training, providers will meet the 8-hour SUD training requirement for DEA registrants, effective June 2023 as part of the MATE Act.

Learning Objectives

At the conclusion of this training participants should be able to:

Screen and identify patients with OUD and define evidence-based treatments.
Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
Explain the process of buprenorphine induction as well as stabilization and maintenance.
Discuss all FDA approved antagonist and agonist medications to treat OUD.
Discuss basic office protocols including medical record documentation and confidentiality.
Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.

American Academy of Addiction Psychiatry (AAAP) is the Data 2000 Sponsor for this training.

Funding for this initiative was made possible (in part) by grant no. 6H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Learn More about expanding access to buprenorphine